Pitavastatin increases HDL particles functionally preserved with cholesterol efflux capacity and antioxidative actions in dyslipidemic patients

Journal of Atherosclerosis and Thrombosis

Volumn 20, Issue 9, 2013, Pages 708-716

  Miyamoto Sasaki, Maki ^a   Yasuda, Tomoyuki ^a   Monguchi, Tomoko ^a   Nakajima, Hideto ^a   Mori, Kenta ^a   Toh, Ryuji ^a   Ishida, Tatsuro ^a   Hirata, Ken Ichi ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Cholesterol efflux; HDL; PON 1; Statin

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN A2; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MACROGOL; N (2,2,2 TRIFLUOROETHYL) N [4 (2,2,2 TRIFLUORO 1 HYDROXY 1 TRIFLUOROMETHYLETHYL)PHENYL]BENZENESULFONAMIDE; PHOSPHOLIPID; PITAVASTATIN; TRIACYLGLYCEROL;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL ARTICLE; DYSLIPIDEMIA; EFFUSION; ENZYME ACTIVITY; ENZYME CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID ANALYSIS; MALE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADULT; AGED; ANTIOXIDANTS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CHOLESTEROL; CHOLESTEROL, HDL; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PLATELET ACTIVATING FACTOR; POLYETHYLENE GLYCOLS; QUINOLINES;

EID: 84884585669     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.17210     Document Type: Article

References (38)

1. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, Peto R, Barnes EH, Keech A, Simes J, Collins R: Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170, 000 participants in 26 randomised trials. Lancet, 2010; 376: 1670-1681
2. Mora S, Wenger NK, Demicco DA, Breazna A, Boekholdt SM, Arsenault BJ, Deedwania P, Kastelein JJ, Waters DD: Determinants of residual risk in secondary prevention patients treated with high-versus low-dose statin therapy: The treating to new targets (tnt) study. Circulation, 2012; 125: 1979-1987
3. Castelli WP: Cholesterol and lipids in the risk of coronary artery disease--the framingham heart study. Can J Cardiol, 1988; 4 Suppl A: 5A-10A
4. Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC: HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med, 2007; 357: 1301-1310
5. Rader DJ, Alexander ET, Weibel GL, Billheimer J, Rothblat GH: The role of reverse cholesterol transport in animals and humans and relationship to atherosclerosis. J Lipid Res, 2009; 50 Suppl: S189-194
6. Barter PJ, Nicholls S, Rye KA, Anantharamaiah GM, Navab M, Fogelman AM: Antiinflammatory properties of HDL. Circ Res, 2004; 95: 764-772
7. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122
8. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: Proatherogenic HDL--an evolving field. Nat Clin Pract Endocrinol Metab, 2006; 2: 504-511
9. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM: The role of dysfunctional HDL in atherosclerosis. J Lipid Res, 2009; 50 Suppl: S145-149
10. Yamashita S, Tsubakio-Yamamoto K, Ohama T, Nakagawa-Toyama Y, Nishida M: Molecular mechanisms of HDL-cholesterol elevation by statins and its effects on HDL functions. J Atheroscler Thromb, 2010; 17: 436-451
11. Fukutomi T, Takeda Y, Suzuki S, Ito T, Joh T, Itoh M: High density lipoprotein cholesterol and apolipoprotein A-I are persistently elevated during long-term treatment with pitavastatin, a new HMG-CoA reductase inhibitor. Int J Cardiol, 2010; 141: 320-322
12. Teramoto T, Shimano H, Yokote K, Urashima M: Effects of pitavastatin (livalo tablet) on high density lipoprotein cholesterol (HDL-c) in hypercholesterolemia. J Atheroscler Thromb, 2009; 16: 654-661
13. Maruyama T, Takada M, Nishibori Y, Fujita K, Miki K, Masuda S, Horimatsu T, Hasuike T: Comparison of preventive effect on cardiovascular events with different statins.-the CIRCLE study. Circ J, 2011; 75: 1951-1959
14. Maejima T, Yamazaki H, Aoki T, Tamaki T, Sato F, Kitahara M, Saito Y: Effect of pitavastatin on apolipoprotein A-I production in hepg2 cell. Biochem Biophys Res Commun, 2004; 324: 835-839
15. Kawano M, Nagasaka S, Yagyu H, Ishibashi S: Pitavas tatin decreases plasma prebeta1-HDL concentration and might promote its disappearance rate in hypercholesterolemic patients. J Atheroscler Thromb, 2008; 15: 41-46
16. Kojima Y, Ishida T, Sun L, Yasuda T, Toh R, Rikitake Y, Fukuda A, Kume N, Koshiyama H, Taniguchi A, Hirata K: Pitavastatin decreases the expression of endothelial lipase both in vitro and in vivo. Cardiovasc Res, 2010; 87: 385-393
17. Teramoto T, Sasaki J, Ueshima H, Egusa G, Kinoshita M, Shimamoto K, Daida H, Biro S, Hirobe K, Funahashi T, Yokote K, Yokode M: Diagnostic criteria for dyslipidemia. Executive summary of Japan atherosclerosis society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb, 2007; 14: 155-158
18. Yvan-Charvet L, Kling J, Pagler T, Li H, Hubbard B, Fisher T, Sparrow CP, Taggart AK, Tall AR: Cholesterol efflux potential and antiinflammatory properties of highdensity lipoprotein after treatment with niacin or anacetrapib. Arterioscler Thromb Vasc Biol, 2010; 30: 1430-1438
19. Schissel SL, Tweedie-Hardman J, Rapp JH, Graham G, Williams KJ, Tabas I: Rabbit aorta and human atherosclerotic lesions hydrolyze the sphingomyelin of retained lowdensity lipoprotein. Proposed role for arterial-wall sphingomyelinase in subendothelial retention and aggregation of atherogenic lipoproteins. J Clin Invest, 1996; 98: 1455-1464
20. Basu SK, Goldstein JL, Anderson GW, Brown MS: Degradation of cationized low density lipoprotein and regulation of cholesterol metabolism in homozygous familial hypercholesterolemia fibroblasts. Proc Natl Acad Sci U S A, 1976; 73: 3178-3182
21. Usui S, Hara Y, Hosaki S, Okazaki M: A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res, 2002; 43: 805-814
22. Hara T, Ishida T, Kojima Y, Tanaka H, Yasuda T, Shinohara M, Toh R, Hirata K: Targeted deletion of endothelial lipase increases HDL particles with anti-inflammatory properties both in vitro and in vivo. J Lipid Res, 2011; 52: 57-67
23. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M, Mackness M: Low paraoxonase activity predicts coronary events in the caerphilly prospective study. Circulation, 2003; 107: 2775-2779
24. Van Lenten BJ, Hama SY, de Beer FC, Stafforini DM, McIntyre TM, Prescott SM, La Du BN, Fogelman AM, Navab M: Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest, 1995; 96: 2758-2767
25. Duffy D, Rader DJ: Update on strategies to increase HDL quantity and function. Nat Rev Cardiol, 2009; 6: 455-463
26. Khera AV, Cuchel M, de la Llera-Moya M, Rodrigues A, Burke MF, Jafri K, French BC, Phillips JA, Mucksavage ML, Wilensky RL, Mohler ER, Rothblat GH, Rader DJ: Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. N Engl J Med, 2011; 364: 127-135
27. Patel PJ, Khera AV, Jafri K, Wilensky RL, Rader DJ: The anti-oxidative capacity of high-density lipoprotein is reduced in acute coronary syndrome but not in stable coronary artery disease. J Am Coll Cardiol, 2011; 58: 2068-2075
28. Sasaki J, Ikeda Y, Kuribayashi T, Kajiwara K, Biro S, Yamamoto K, Ageta M, Kobori S, Saikawa T, Otonari T, Kono S: A 52-week, randomized, open-label, parallelgroup comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther, 2008; 30: 1089-1101
29. Kobayashi M, Gouda K, Chisaki I, Ochiai M, Itagaki S, Iseki K: Regulation mechanism of ABCA1 expression by statins in hepatocytes. Eur J Pharmacol, 2011; 662: 9-14
30. Wang X, Collins HL, Ranalletta M, Fuki IV, Billheimer JT, Rothblat GH, Tall AR, Rader DJ: Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest, 2007; 117: 2216-2224
31. Yancey PG, Kawashiri MA, Moore R, Glick JM, Williams DL, Connelly MA, Rader DJ, Rothblat GH: In vivo modulation of HDL phospholipid has opposing effects on SR-BI-and ABCA1-mediated cholesterol efflux. J Lipid Res, 2004; 45: 337-346
32. Harangi M, Seres I, Harangi J, Paragh G: Benefits and difficulties in measuring HDL subfractions and human paraoxonase-1 activity during statin treatment. Cardiovasc Drugs Ther, 2009; 23: 501-510
33. Ota K, Suehiro T, Arii K, Ikeda Y, Kumon Y, Osaki F, Hashimoto K: Effect of pitavastatin on transactivation of human serum paraoxonase 1 gene. Metabolism, 2005; 54: 142-150
34. Tani S, Watanabe I, Anazawa T, Kawamata H, Tachibana E, Furukawa K, Sato Y, Nagao K, Kanmatsuse K, Kushiro T: Effect of pravastatin on malondialdehyde-modified low-density lipoprotein levels and coronary plaque regression as determined by three-dimensional intravascular ultrasound. Am J Cardiol, 2005; 96: 1089-1094
35. Takayama T, Hiro T, Yamagishi M, Daida H, Hirayama A, Saito S, Yamaguchi T, Matsuzaki M: Effect of rosuvastatin on coronary atheroma in stable coronary artery disease: Multicenter coronary atherosclerosis study measuring effects of rosuvastatin using intravascular ultrasound in Japanese subjects (cosmos). Circ J, 2009; 73: 2110-2117
36. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099
37. Yvan-Charvet L, Matsuura F, Wang N, Bamberger MJ, Nguyen T, Rinninger F, Jiang XC, Shear CL, Tall AR: Inhibition of cholesteryl ester transfer protein by torcetrapib modestly increases macrophage cholesterol efflux to HDL. Arterioscler Thromb Vasc Biol, 2007; 27: 1132-1138
38. Chantepie S, Bochem AE, Chapman MJ, Hovingh GK, Kontush A: High-density lipoprotein (HDL) particle subpopulations in heterozygous cholesteryl ester transfer protein (cetp) deficiency: Maintenance of antioxidative activity. PLoS One, 2012; 7: e49336